Abstract
Resveratrol, a polyphenol abundantly found in grapes and red wine, exhibits beneficial health effects due to its anti-inflammatory properties. In the present study, we evaluated the effect of resveratrol on inflammatory responses induced by lipopolysaccharide (LPS) treatment of human intestinal Caco-2 and SW480 cell lines. In the LPS-treated intestinal cells, resveratrol dose-dependently inhibited the expression of inducible NO synthase (iNOS) mRNA as well as protein expression, resulting in a decreased production of NO. In addition, Toll-like receptor-4 expression was significantly diminished in LPS-stimulated cells after resveratrol pre-treatment. To investigate the mechanisms by which resveratrol reduces NO production and iNOS expression, we examined the activation of inhibitor of κB (IκB) in LPS-stimulated intestinal cells. Results demonstrated that resveratrol inhibited the phosphorylation, as well as the degradation, of the IκB complex. Overall, these results show that resveratrol is able to reduce LPS-induced inflammatory responses by intestinal cells, interfering with the activation of NF-κB-dependent molecular mechanisms.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Anti-Inflammatory Agents, Non-Steroidal / adverse effects
-
Anti-Inflammatory Agents, Non-Steroidal / metabolism*
-
Anti-Inflammatory Agents, Non-Steroidal / therapeutic use
-
Antineoplastic Agents, Phytogenic / adverse effects
-
Antineoplastic Agents, Phytogenic / metabolism*
-
Antineoplastic Agents, Phytogenic / therapeutic use
-
Caco-2 Cells
-
Cell Line, Tumor
-
Cell Survival
-
Colonic Neoplasms / immunology
-
Colonic Neoplasms / metabolism*
-
Colonic Neoplasms / pathology
-
Colonic Neoplasms / prevention & control
-
Dietary Supplements / adverse effects
-
Down-Regulation
-
Enterocytes / cytology
-
Enterocytes / immunology
-
Enterocytes / metabolism*
-
Enterocytes / pathology
-
Humans
-
I-kappa B Proteins / metabolism
-
Inflammatory Bowel Diseases / diet therapy
-
Inflammatory Bowel Diseases / immunology
-
Inflammatory Bowel Diseases / metabolism*
-
Inflammatory Bowel Diseases / pathology
-
Lipopolysaccharides
-
NF-kappa B / antagonists & inhibitors*
-
NF-kappa B / metabolism
-
Nitric Oxide / metabolism
-
Nitric Oxide Synthase Type II / genetics
-
Nitric Oxide Synthase Type II / metabolism
-
Phosphorylation
-
Protein Processing, Post-Translational
-
Proteolysis
-
RNA, Messenger / metabolism
-
Resveratrol
-
Stilbenes / adverse effects
-
Stilbenes / metabolism*
-
Stilbenes / therapeutic use
-
Toll-Like Receptor 4 / genetics
-
Toll-Like Receptor 4 / metabolism
Substances
-
Anti-Inflammatory Agents, Non-Steroidal
-
Antineoplastic Agents, Phytogenic
-
I-kappa B Proteins
-
Lipopolysaccharides
-
NF-kappa B
-
RNA, Messenger
-
Stilbenes
-
TLR4 protein, human
-
Toll-Like Receptor 4
-
Nitric Oxide
-
NOS2 protein, human
-
Nitric Oxide Synthase Type II
-
Resveratrol